Neuroscience

Neuroscience innovation
#Animal models #Animal testing #Events #Neuroscience #Neuroscience 2024 #Society for Neuroscience

Neuroscience 2024: Animals in research

DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having published a general event roundup, here she unpacks the ‘Animals in Research’ panel: Lifesaving clinical advances stemming from animal research, which took place on Monday 7 October. The panellists included Walter Koroshetz,… Read More

#Exclusive Content #Opinion #Regulatory

#Neuroscience

App Note: Disease modelling with genetically matched iPSC-derived excitatory neurons

Download bit.bio’s application note to learn more about: Functional characterisation of human iPSC-derived ALS disease models using high throughput MEA. Phenotypic data showing reduced neuronal activity and network formation in ALS disease models. A genetically matched system in ioGlutamatergic Neurons that can be used to identify, measure and rescue disease-related… Read More

#App Notes

Gene therapy
#FDA #Gene therapy #Neurology #Neuroscience #PTC Therapeutics #Rare disease

FDA approves first gene therapy for rare genetic disorder

The US Food and Drug Administration (FDA) has approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters,… Read More

#News #Regulatory

#Centessa Pharmaceuticals #Clinical trials #Narcolepsy #Neuroscience #Sleep disorders

Centessa initiates Phase II trial in patients with sleep/wake disorders 

Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.  ORX750 was designed using Nxera Pharma technology to directly… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

New DDW Highlights episode: 11 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

This week in drug discovery (4-8 November) 

News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. The top stories:… Read More

#News

Neuroscience innovation
#Brain #Comment #Events #Neuroscience #Neuroscience 2024 #Society for Neuroscience

Reflections from SfN’s Neuroscience 2024 

DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having attended a range of presentations, explored the exhibition and engaged with industry attendees, she reflects on the event.   News updates  Whilst Neuroscience 2024 took place, the 2024 Nobel Prizes were announced. For… Read More

#Exclusive Content

Mitochondria
#Mitochondria #Neuroscience #NRG Therapeutics #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. The company says NRG5051 also has potential in other neurological diseases such as amyotrophic lateral sclerosis (ALS). Read More

#Business & Investment #Editor's Choice #News

Tau proteins
#Alzheimer's #Neuroscience #Phase II trial #Tau protein #UCB

Encouraging results for anti-tau antibody presented at CTAD 2024

UCB has reported encouraging Phase IIa data from the TOGETHER (AH0003) study, investigating bepranemab, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease. The results were presented during a late-breaking symposium at the 2024 Clinical Trials… Read More

#News

Neuroscience innovation
#Drug development #Drug discovery #Neuroscience #Webinar

Watch DDW’s Neuroscience Showcase On Demand

In this free online event at 3pm BST on 24 October, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector.  The showcase includes a panel discussion looking at… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Motor neurone disease #Neurodegenerative disorders #Neuroscience #Nevrargenics

Promising new therapy for ALS progresses to human trials

A new treatment for the most common type of motor neurone disease (MND) could improve the neuronal health of sufferers and allow their nervous systems to improve regeneration. Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a… Read More

#News

Neuron
#Neurology #Neuroscience #Precision medicine #Psychiatry #Webinar

Watch now! DDW Neuroscience Showcase

In this free online event hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel discussion looking at the use of new drug discovery… Read More

#News

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

New DDW Highlights episode: 15 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience’s annual meeting took place, so… Read More

#News

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

This week in drug discovery (7-11 Oct) 

News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer. The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1… Read More

#News